Matches in SemOpenAlex for { <https://semopenalex.org/work/W3009778907> ?p ?o ?g. }
Showing items 1 to 91 of
91
with 100 items per page.
- W3009778907 endingPage "15080" @default.
- W3009778907 startingPage "15080" @default.
- W3009778907 abstract "15080 Background: The reported activity of docetaxel in pancreatic cancer and high level of EGFR expression in pancreatic carcinomas led us to examine the efficacy of combination docetaxel and gefitinib in patients with metastatic pancreatic cancer. Methods: Eligibility criteria included PS = 1, failed prior adjuvant ot metastatic gemcitabine-containing regimen, = 1 prior regimen for metastatic disease, no prior taxane or EGFR inhibitor, and adequate organ function. Patients received docetaxel 40 mg/m2 intravenously weekly for 2 of every 3 weeks and daily oral gefitinib 250 mg. The primary endpoint was CA19–9 response (>50% decrease in tumor marker CA19–9 levels). Additional endpoints included radiologic response, toxicity, and survival. Results: Fifteen patients received docetaxel and gefitinib between 11/2/04 and 11/26/05. The median age of patients was 60 (46–76), and included 7 women and 8 men. The regimen was generally well tolerated, and there were no unanticipated toxicities. Grade 3 or 4 toxicities included lymphopenia (6 pts), hyperglycemia (3 pts), leucopenia (3 pts), infection (2 pts), fatigue (2 pts), elevated transaminases (2 pts), neutropenia (2 pts), pleural effusion (2 pts), irregular menses (1 pt), anorexia (1 pt), dysphagia/esophagitis (1 pt), diarrhea (1 pt), alkaline phosphatase (1 pt), and sensory neuropathy (1 pt). No treatment-related deaths occurred. No patient experienced a biochemical (CA 19–9) response to treatment. All 15 patients were evaluable for radiologic response, of which 9 experienced stable disease and 6 progressive disease as their best response to therapy. The trial was stopped due to lack of efficacy, in accordance with an early stopping rule incorporated into the trial design. Conclusions: In the doses and schedule used in this trial, the combination of docetaxel and gefitinib does not appear to be active in patients with pancreatic cancer who have failed prior gemcitabine-based chemotherapy. No significant financial relationships to disclose." @default.
- W3009778907 created "2020-03-13" @default.
- W3009778907 creator A5002447665 @default.
- W3009778907 creator A5017947396 @default.
- W3009778907 creator A5022221962 @default.
- W3009778907 creator A5049314303 @default.
- W3009778907 creator A5070720153 @default.
- W3009778907 creator A5075051023 @default.
- W3009778907 creator A5075625649 @default.
- W3009778907 creator A5081543892 @default.
- W3009778907 creator A5088566246 @default.
- W3009778907 creator A5090604653 @default.
- W3009778907 date "2007-06-20" @default.
- W3009778907 modified "2023-10-16" @default.
- W3009778907 title "A phase II study of docetaxel in combination with ZD1839 (gefitinib) in previously treated patients with metastatic pancreatic cancer" @default.
- W3009778907 doi "https://doi.org/10.1200/jco.2007.25.18_suppl.15080" @default.
- W3009778907 hasPublicationYear "2007" @default.
- W3009778907 type Work @default.
- W3009778907 sameAs 3009778907 @default.
- W3009778907 citedByCount "9" @default.
- W3009778907 countsByYear W30097789072015 @default.
- W3009778907 crossrefType "journal-article" @default.
- W3009778907 hasAuthorship W3009778907A5002447665 @default.
- W3009778907 hasAuthorship W3009778907A5017947396 @default.
- W3009778907 hasAuthorship W3009778907A5022221962 @default.
- W3009778907 hasAuthorship W3009778907A5049314303 @default.
- W3009778907 hasAuthorship W3009778907A5070720153 @default.
- W3009778907 hasAuthorship W3009778907A5075051023 @default.
- W3009778907 hasAuthorship W3009778907A5075625649 @default.
- W3009778907 hasAuthorship W3009778907A5081543892 @default.
- W3009778907 hasAuthorship W3009778907A5088566246 @default.
- W3009778907 hasAuthorship W3009778907A5090604653 @default.
- W3009778907 hasConcept C121608353 @default.
- W3009778907 hasConcept C126322002 @default.
- W3009778907 hasConcept C141071460 @default.
- W3009778907 hasConcept C143998085 @default.
- W3009778907 hasConcept C203092338 @default.
- W3009778907 hasConcept C2776694085 @default.
- W3009778907 hasConcept C2776907518 @default.
- W3009778907 hasConcept C2777063308 @default.
- W3009778907 hasConcept C2777511904 @default.
- W3009778907 hasConcept C2778822529 @default.
- W3009778907 hasConcept C2779438470 @default.
- W3009778907 hasConcept C2780258809 @default.
- W3009778907 hasConcept C2780580887 @default.
- W3009778907 hasConcept C2781190966 @default.
- W3009778907 hasConcept C2781413609 @default.
- W3009778907 hasConcept C530470458 @default.
- W3009778907 hasConcept C535046627 @default.
- W3009778907 hasConcept C71924100 @default.
- W3009778907 hasConcept C90924648 @default.
- W3009778907 hasConceptScore W3009778907C121608353 @default.
- W3009778907 hasConceptScore W3009778907C126322002 @default.
- W3009778907 hasConceptScore W3009778907C141071460 @default.
- W3009778907 hasConceptScore W3009778907C143998085 @default.
- W3009778907 hasConceptScore W3009778907C203092338 @default.
- W3009778907 hasConceptScore W3009778907C2776694085 @default.
- W3009778907 hasConceptScore W3009778907C2776907518 @default.
- W3009778907 hasConceptScore W3009778907C2777063308 @default.
- W3009778907 hasConceptScore W3009778907C2777511904 @default.
- W3009778907 hasConceptScore W3009778907C2778822529 @default.
- W3009778907 hasConceptScore W3009778907C2779438470 @default.
- W3009778907 hasConceptScore W3009778907C2780258809 @default.
- W3009778907 hasConceptScore W3009778907C2780580887 @default.
- W3009778907 hasConceptScore W3009778907C2781190966 @default.
- W3009778907 hasConceptScore W3009778907C2781413609 @default.
- W3009778907 hasConceptScore W3009778907C530470458 @default.
- W3009778907 hasConceptScore W3009778907C535046627 @default.
- W3009778907 hasConceptScore W3009778907C71924100 @default.
- W3009778907 hasConceptScore W3009778907C90924648 @default.
- W3009778907 hasIssue "18_suppl" @default.
- W3009778907 hasLocation W30097789071 @default.
- W3009778907 hasOpenAccess W3009778907 @default.
- W3009778907 hasPrimaryLocation W30097789071 @default.
- W3009778907 hasRelatedWork W1606976179 @default.
- W3009778907 hasRelatedWork W1983722681 @default.
- W3009778907 hasRelatedWork W1987807424 @default.
- W3009778907 hasRelatedWork W1990777236 @default.
- W3009778907 hasRelatedWork W2014768677 @default.
- W3009778907 hasRelatedWork W2071420550 @default.
- W3009778907 hasRelatedWork W2093981422 @default.
- W3009778907 hasRelatedWork W2124697776 @default.
- W3009778907 hasRelatedWork W2138054646 @default.
- W3009778907 hasRelatedWork W4237106514 @default.
- W3009778907 hasVolume "25" @default.
- W3009778907 isParatext "false" @default.
- W3009778907 isRetracted "false" @default.
- W3009778907 magId "3009778907" @default.
- W3009778907 workType "article" @default.